Clinical Trial Update: To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety of adding SAR153191 (REGN88) and tocilizumab to other rheumatoid arthritis therapies in patients who do not respond to or ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• SAR153191 (REGN88) (SAR153191)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Sanofi | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-06-26